2025 annual financial data

China SXT Pharmaceuticals 2025 Net margin

China SXT Pharmaceuticals 2025 net margin with verified reported values.

Direct answer

Net margin was -189.77%.

Operating income was -2,680,479 USD and net income was -3,303,652 USD.
Operating cash flow was -2,345,333 USD.

Get free China SXT Pharmaceuticals email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
1,740,907 USD
Operating income
-2,680,479 USD
Net income
-3,303,652 USD
Operating cash flow
-2,345,333 USD